INOVIO is a commercial-stage biotechnology company that develops DNA medicines to treat and protect against HPV-related diseases, cancer and infectious diseases. Its platform has two parts: proprietary plasmid DNA designs, which are small circular DNA molecules that instruct the body's cells to produce specific disease-fighting proteins, and its CELLECTRA electroporation delivery devices. These devices deliver the DNA without chemical adjuvants, lipid nanoparticles or viral vectors. The company's first commercial product, VOCERYQ, received FDA accelerated approval in October 2026 to reduce the frequency of surgery in adults with Recurrent Respiratory Papillomatosis (RRP). RRP is a rare HPV-6/11-driven disease, and INOVIO estimates at least 25,000 prevalent patients in the U.S. VOCERYQ is administered with the CELLECTRA 5PSP device over a 9-week regimen and holds FDA Orphan Drug and Breakthrough Therapy designations plus EU Orphan Drug designation. Commercial launch is planned for Q1 2027, supported by Syneos Health for field team deployment. INOVIO also generates modest revenue from collaborative arrangements. It is seeking partners for its next-generation DNA-Encoded Protein (DPROT) programs targeting rare diseases such as Hemophilia A, Fabry Disease and hypophosphatasia. Updated
Wednesday afternoon's top analyst upgrades and downgrades included Inovio Pharmaceuticals, McDonald’s, Orchard Therapeutics, VBI Vaccines and Wingstop.
Things aren’t looking up for Inovio Pharmaceuticals, after the FDA notified the company that it was placing a partial hold on its COVID-19 vaccine study.
Inovio Pharmaceuticals has announced that it received $71 million in funding from the U.S. Department of Defense to support the production of its delivery device for the COVID-19 vaccine.
Thursday's top analyst upgrades and downgrades included Aerojet Rocketdyne, Avis Budget, Carnival, Chipotle Mexican Grill, Expedia, Home Depot, Lowe's, MGM Resorts, Stratasys, Square and Walmart.
Wednesday's top analyst upgrades and downgrades included Alphabet, Advanced Micro Devices, Corning, FireEye, Inovia Pharmaceuticals, Lululemon Athletica, Nike, Roku, Starbucks, Tyson Foods and Walmart.
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine, treatment or test to deal with this coronavirus and here is where their stocks stand now.
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine, treatment or test to deal with this novel coronavirus. Here's how they fared as the week wound…
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine to deal with this novel coronavirus and where they stand now.
Markets looked like they would be crushed yet again on Monday. 24/7 Wall St. has tracked some stocks that either are defensive in general or were defying Monday’s big drop.
INOVIO is a commercial-stage biotechnology company that develops DNA medicines to treat and protect against HPV-related diseases, cancer and infectious diseases.